Lexaria Bioscience (LEXX) Gross Margin (2017 - 2026)
Lexaria Bioscience (LEXX) posted Gross Margin of 100.0% for Q1 2026, little changed sequentially from 100.0% in Q3 2025, and little changed YoY from 100.0% in Q1 2025.
Lexaria Bioscience (LEXX) Gross Margin (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Gross Margin for 10 years, with the latest figure at 100.0% in Q1 2026.
- Quarterly Gross Margin changed 0.0% year-over-year to 100.0% in Q1 2026, while the trailing twelve-month figure through May 2026 was 100.0% (up 44.0% YoY) and the FY2025 annual result came in at 99.61%, up 65.0% from the prior year.
- Gross Margin was little changed at 100.0% in Q1 2026 per LEXX's latest filing, from 100.0% in the prior quarter.
- Over five years, Gross Margin peaked at 571.57% in Q1 2023 and troughed at 62.89% in Q3 2022.
- A 5-year average of 122.36% and a median of 100.0% in 2023 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2024: Gross Margin soared 49240 bps in 2023, then slumped 47157 bps in 2024.
- Over 5 years, Gross Margin stood at 83.84% in 2022, then grew by 15 bps to 96.81% in 2023, then increased by 2 bps to 98.52% in 2024, then grew by 2 bps to 100.0% in 2025, then changed by 0 bps to 100.0% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 100.0%, 100.0%, and 100.0% for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 100.00% |
| Aug 31, 2025 | 100.00% |
| May 31, 2025 | 100.00% |
| Feb 28, 2025 | 100.00% |
| Nov 30, 2024 | 98.52% |
| Aug 31, 2024 | 100.00% |
| May 31, 2024 | 100.00% |
| Feb 29, 2024 | 100.00% |
| Nov 30, 2023 | 96.81% |
| Aug 31, 2023 | 100.00% |
| May 31, 2023 | 83.60% |
| Feb 28, 2023 | 571.57% |
| Nov 30, 2022 | 83.84% |
| Aug 31, 2022 | 62.89% |
| May 31, 2022 | 81.31% |
| Feb 28, 2022 | 79.16% |
| Nov 30, 2021 | 59.87% |
| Aug 31, 2021 | 34.53% |
| May 31, 2021 | 70.60% |
| Feb 28, 2021 | 84.08% |